The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

Opportunistic fungal pathogens may cause superficial or serious invasive infections,
especially in immunocompromised and debilitated patients. Invasive mycoses represent an …

There are currently few antifungals in use which show efficacy against fungal diseases.
These antifungals mostly target specific components of fungal plasma membrane or its …

Invasive fungal infections remain a major source of global morbidity and mortality, especially
among patients with underlying immune suppression. Successful patient management …

Pdr5, a member of the extensive ABC transporter superfamily, is representative of a clinically
relevant subgroup involved in pleiotropic drug resistance. Pdr5 and its homologues drive …

Abstract In Candida albicans, Cdr1 pumps azole drugs out of the cells to reduce intracellular
accumulation at detrimental concentrations, leading to azole-drug resistance. Milbemycin …

Overexpression of the ATP-binding cassette (ABC) drug transporter P-glycoprotein (P-gp) is
often responsible for the failure of chemotherapy as a treatment for human tumors. The …

Resistance to antifungal drugs is an increasingly significant clinical problem. The most
common antifungal resistance encountered is efflux pump-mediated resistance of Candida …

Background The superfamily of ABC proteins is among the largest known in nature. Its
members are mainly, but not exclusively, involved in the transport of a broad range of …